New York Senate Bill S07342

New York 2025-2026 Regular Session

• Introduced: 4/10/25
• Refer: 4/10/25
• Refer: 1/7/26

Caption

Prohibits the administration of COVID-19 mRNA vaccinations; requires the department of health to conduct a study and make recommendations on the benefits and risks of the administration of such vaccines; requires a self-controlled case series to be completed; makes related provisions.

Summary

S07342 would prohibit the administration of COVID-19 mRNA vaccinations in New York unless and until the state Department of Health completes an analysis of existing data and concludes that the benefits outweigh the risks. The bill also directs the department to conduct a study and issue recommendations on the benefits and risks of these vaccines, including a self-controlled case series, to be completed within one year of the act’s effective date. Under the bill, COVID-19 mRNA vaccination could resume only after the Department of Health determines that the vaccines are safe. The measure takes effect immediately and would therefore create an immediate statewide restriction on the use of COVID-19 mRNA vaccines pending the required review.

Impact

The bill would significantly alter state public health policy by restricting the administration of COVID-19 mRNA vaccines and conditioning their continued use on a state-level safety determination. It would place the New York Department of Health in the role of conducting a formal risk-benefit review and producing recommendations, including a specific epidemiological study design, before vaccination could continue. The practical effect would be to affect healthcare providers, vaccination programs, public health agencies, and residents seeking COVID-19 vaccination, while also potentially conflicting with existing vaccine guidance and public health practice.

Sentiment

The bill text reflects a strongly skeptical posture toward COVID-19 mRNA vaccines, since it presumes a prohibition unless the Department of Health affirmatively validates their safety and benefits. No committee transcripts or recorded votes were provided, so there is no documented legislative debate or vote history to indicate broader support or opposition. Based on the bill’s framing alone, the measure appears to be driven by concern over vaccine risks rather than by a consensus public health approach.

Contention

The central point of contention is whether the state should prohibit COVID-19 mRNA vaccinations pending a new state study, or whether such a restriction would be unwarranted given existing scientific review and public health guidance. Supporters would likely emphasize caution, additional data collection, and the need for a state-specific safety analysis. Opponents would likely argue that the bill could undermine vaccine access, conflict with established medical consensus, and interfere with public health efforts. The requirement for a self-controlled case series and the condition that vaccines may resume only after a safety finding are likely to be especially controversial.